[go: up one dir, main page]

CO2017005578A2 - Unidad de dispositivo de droga que contiene quinagolida - Google Patents

Unidad de dispositivo de droga que contiene quinagolida

Info

Publication number
CO2017005578A2
CO2017005578A2 CONC2017/0005578A CO2017005578A CO2017005578A2 CO 2017005578 A2 CO2017005578 A2 CO 2017005578A2 CO 2017005578 A CO2017005578 A CO 2017005578A CO 2017005578 A2 CO2017005578 A2 CO 2017005578A2
Authority
CO
Colombia
Prior art keywords
drug device
device unit
quinagolide
unit containing
polyalkylene oxide
Prior art date
Application number
CONC2017/0005578A
Other languages
English (en)
Inventor
Janet Halliday
Denis Carr
Alistair Ross
Claire Young
Paul Mcdonald
Mohammad Qadir
Robert Cochrane
Gouher Rabani
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017005578(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CO2017005578A2 publication Critical patent/CO2017005578A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/001—Combinations of extrusion moulding with other shaping operations
    • B29C48/0021—Combinations of extrusion moulding with other shaping operations combined with joining, lining or laminating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor
    • B29L2031/754—Pessaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se basa en la identificación de una cohorte de copolímeros de bloque de poliuretano que son particularmente adecuados para uso en unidades farmacéuticas de dispositivo de droga polimérica y el cual ofrece control mejorado de liberación de droga. En particular, se suministra una unidad de dispositivo de droga polimérica que comprende un copolímero de bloque de poliuretano obtenido al reaccionar junto con un poli(óxido de alquileno); un compuesto difuncional; un isocianato difuncional; y opcionalmente un copolímero de bloque que comprende bloques de poli(óxido de alquileno); y quinagolida como un agente farmacéuticamente activo. Las unidades de dispositivo de droga pueden encontrar aplicación en el tratamiento y/o prevención de endometriosis.
CONC2017/0005578A 2014-11-07 2017-06-05 Unidad de dispositivo de droga que contiene quinagolida CO2017005578A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192372.2A EP3017809A1 (en) 2014-11-07 2014-11-07 Drug-device unit containing quinagolide
PCT/EP2015/075849 WO2016071466A1 (en) 2014-11-07 2015-11-05 Drug-device unit containing quinagolide

Publications (1)

Publication Number Publication Date
CO2017005578A2 true CO2017005578A2 (es) 2017-08-31

Family

ID=51951583

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005578A CO2017005578A2 (es) 2014-11-07 2017-06-05 Unidad de dispositivo de droga que contiene quinagolida

Country Status (34)

Country Link
US (2) US20180008535A1 (es)
EP (3) EP3017809A1 (es)
JP (2) JP6907120B2 (es)
KR (1) KR102612852B1 (es)
CN (2) CN116212032A (es)
AR (1) AR102571A1 (es)
AU (2) AU2015341734C1 (es)
CA (1) CA2966473A1 (es)
CL (1) CL2017001119A1 (es)
CO (1) CO2017005578A2 (es)
DK (1) DK3215118T3 (es)
EA (2) EA033806B9 (es)
ES (1) ES2877973T3 (es)
HR (1) HRP20210961T1 (es)
HU (1) HUE054951T2 (es)
IL (1) IL252088B (es)
JO (1) JO3561B1 (es)
LT (1) LT3215118T (es)
MA (2) MA40897B1 (es)
MD (1) MD3215118T2 (es)
MX (1) MX379298B (es)
MY (1) MY193638A (es)
NZ (1) NZ731763A (es)
PH (1) PH12017550005A1 (es)
PL (1) PL3215118T3 (es)
PT (1) PT3215118T (es)
RS (1) RS62018B1 (es)
SA (1) SA517381471B1 (es)
SG (1) SG11201703596SA (es)
SI (1) SI3215118T1 (es)
TN (1) TN2017000175A1 (es)
TW (1) TWI685339B (es)
UA (1) UA122329C2 (es)
WO (1) WO2016071466A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020091456A1 (ko) 2018-10-31 2020-05-07 ㈜아모레퍼시픽 바이오 폴리머를 포함하는 코어-쉘 네트워크 구조체 및 이를 포함하는 조성물
KR20210069344A (ko) 2019-12-03 2021-06-11 (주)아모레퍼시픽 바이오 폴리머를 포함하는 효능물질 전달체
US20240361338A1 (en) 2021-08-31 2024-10-31 Ferring B.V. Diagnosis and treatment of ectopic endometriosis
WO2024153752A1 (en) 2023-01-20 2024-07-25 Ferring B.V. Stereoselective synthesis of intermediates and synthesis of quinagolids
WO2025093626A1 (en) * 2023-10-31 2025-05-08 Basf Se Process for producing thermoplastic polyurethanes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235988A (en) 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents
ATE461681T1 (de) 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
CA2531640C (en) 2003-07-10 2013-06-18 Galen (Chemicals) Limited Intravaginal drug delivery devices
WO2005025549A2 (en) * 2003-09-10 2005-03-24 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
WO2006117608A1 (en) 2005-04-29 2006-11-09 Ferring International Center S.A. Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
SA08290041B1 (ar) 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
EP2244782A4 (en) 2008-01-25 2011-09-14 Univ Utah Res Found POLYMER WITH LINEAR ORDER RELEASE
US8383152B2 (en) * 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20100040671A1 (en) 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
US20100210600A1 (en) * 2009-02-19 2010-08-19 Prelief Inc. Methods and Compositions for Treating Urogenital Disorders
WO2010150098A2 (en) * 2009-06-26 2010-12-29 Ferring International Center Sa Treatment of endometriosis
US20110262347A1 (en) * 2010-04-08 2011-10-27 The Salk Institute For Biological Studies Methods and compositions for enhanced delivery of compounds
WO2012066000A1 (en) 2010-11-15 2012-05-24 Dsm Ip Assets B.V. Intravaginal drug delivery device comprising a polyurethane copolymer
MX357598B (es) * 2011-07-20 2018-07-16 F Kiser Patrick Dispositivos intravaginales para administración de fármaco.
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US10413504B2 (en) * 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
EA201790898A1 (ru) 2017-11-30
SG11201703596SA (en) 2017-06-29
HUE054951T2 (hu) 2021-10-28
HRP20210961T1 (hr) 2021-09-17
PT3215118T (pt) 2021-05-31
WO2016071466A1 (en) 2016-05-12
EP3017809A1 (en) 2016-05-11
PH12017550005A1 (en) 2017-10-18
MA40897A (fr) 2017-09-13
TW201625245A (zh) 2016-07-16
ES2877973T3 (es) 2021-11-17
EP3892261A1 (en) 2021-10-13
TN2017000175A1 (en) 2018-10-19
US20180008535A1 (en) 2018-01-11
UA122329C2 (uk) 2020-10-26
AR102571A1 (es) 2017-03-08
LT3215118T (lt) 2021-06-10
AU2015341734B2 (en) 2020-08-20
MX379298B (es) 2025-03-10
SI3215118T1 (sl) 2021-08-31
MA40897B1 (fr) 2021-04-30
US20220040094A1 (en) 2022-02-10
EA033806B1 (ru) 2019-11-27
AU2015341734A1 (en) 2017-06-01
AU2015341734C1 (en) 2020-12-17
CN116212032A (zh) 2023-06-06
KR20170080671A (ko) 2017-07-10
CL2017001119A1 (es) 2018-01-05
JP2017533272A (ja) 2017-11-09
KR102612852B1 (ko) 2023-12-11
JO3561B1 (ar) 2020-07-05
AU2020270480A1 (en) 2020-12-17
JP2021155444A (ja) 2021-10-07
IL252088B (en) 2022-04-01
EP3215118B1 (en) 2021-03-17
MX2017005828A (es) 2017-11-13
SA517381471B1 (ar) 2022-03-06
EA201991882A2 (ru) 2020-01-31
BR112017009476A2 (pt) 2018-01-02
TWI685339B (zh) 2020-02-21
DK3215118T3 (da) 2021-06-21
EP3215118A1 (en) 2017-09-13
CN106999422A (zh) 2017-08-01
JP6907120B2 (ja) 2021-07-21
PL3215118T3 (pl) 2021-07-26
MY193638A (en) 2022-10-21
IL252088A0 (en) 2017-07-31
EA201790898A8 (ru) 2018-01-31
NZ731763A (en) 2024-04-26
EA033806B9 (ru) 2019-12-19
CA2966473A1 (en) 2016-05-12
RS62018B1 (sr) 2021-07-30
MA56414A (fr) 2022-05-04
MD3215118T2 (ro) 2021-08-31

Similar Documents

Publication Publication Date Title
CO2017005578A2 (es) Unidad de dispositivo de droga que contiene quinagolida
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX378273B (es) Compuestos activos hacia bromodominios.
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
NZ726364A (en) Vaccine composition against streptococcus suis infection
BR112017005666A2 (pt) micropartículas injetáveis para liberação hiper-localizada de agentes terapêuticos
BR112015014969A2 (pt) micromatriz para entrega de agente terapêutico e métodos de uso
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
BR112017005361A2 (pt) emplastro de opipramol
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX386234B (es) Vacuna para la malaria.
EP3340988C0 (en) ION CHANNEL INHIBITOR COMPOUNDS, PHARMACEUTICAL FORMULATIONS, AND USES
AR105205A1 (es) Sustrato adhesivo desechable adaptado para ser dispuesto sobre un dispositivo médico
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
DK3707128T3 (da) Injicerbare, farmaceutiske isoxazolinsammensætninger og anvendelse deraf mod parasitangreb
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
PH12017501806A1 (en) Anthelmintic combinations and methods of use thereof
EP3431517A4 (en) Copolymer and surface treatment
BR112018072664A2 (pt) composições e métodos para tratamento de inflamação e infecção do olho
BR112017004552A2 (pt) composições farmacêuticas